Skip to main content
. Author manuscript; available in PMC: 2010 Mar 9.
Published in final edited form as: J Cardiovasc Pharmacol. 2009 Jun;53(6):486–494. doi: 10.1097/FJC.0b013e3181a7b58a

FIGURE 3.

FIGURE 3

Effect of S1P receptor antagonists on S1P-induced ERK activation in adult cardiomyocytes. Panel A. Cardiomyocytes were pretreated for 30 minutes with 1 μM of the S1P1 and S1P3 receptor antagonist VPC23019 before stimulation with S1P (1 μM) for 10 minutes. Panel B. Cardiomyocytes were pretreated for 30 minutes with 1 μM VPC23019 before stimulation with the selective S1P1 receptor agonist SEW2871 (1 μM) for 10 minutes. Panel C. Quiescent cardiomyocytes were pretreated for 30 minutes with 1 μM of the selective S1P3 receptor antagonist CAY10444 before stimulation with either 100 nM (third bar) or 1 μM (fourth bar) S1P for 10 minutes. Equal gel loading was assessed using an antibody against total ERK 1/2. Specific bands corresponding to phosphorylated forms of ERK 1/2 were quantified by densitometry and expressed as a percentage of the corresponding control. Data are expressed as mean ± SEM. *P < 0.05 compared with all other values. For panel A, n = 5 independent experiments; for panel B, n = 6 independent experiments; and for panel C, n = 4 independent experiments. Veh, vehicle.